Brind.
  1. ACR Convergence 2026 is being held in Orlando.

Immutep shifts clinical strategy to HNSCC; IMP761 becomes co-priority

1 report, 1 independent Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Immutep announced it intends to prioritize the registration-directed clinical program for efti in patients with HNSCC. The company also stated that IMP761, an agonist anti-LAG-3 antibody, is now a co-priority alongside efti and will be presented at the American College of Rheumatology Convergence in November 2026. Additionally, Immutep received an A$0.86 million cash rebate from the Australian Government and €1.36 million from the French Government for eligible R&D activities.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The shift in clinical strategy toward HNSCC indicates a change in the company's commercial pipeline for its efti program. The successful resolution of manufacturing issues related to the TACTI-004 trial and the receipt of government R&D incentives support the company's financial runway.

ACR Convergence 2026 is being held in Orlando.

From manilatimes.net

Who's involved

  • ImmutepBiotechnology company presenting clinical strategy updates and receiving R&D funding.
  • American College of RheumatologyProfessional organization where Immutep presented its clinical information.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

Part of

ACR Convergence 2026 is being held in Orlando. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped